Treatment of Diabetes and Osteoporosis—A Reciprocal Risk?

Abstract

Diabetes mellitus is a metabolic and systematic disorder that requires individualized therapy. The disease leads to various consequences, resulting in the destruction of tissues and organs. The aforementioned outcomes also include bone mineral disorders, caused by medications as well as diet therapy and physical activity. Some drugs may have a beneficial effect on both bone mineral density and the risk of fractures. Nevertheless, the impact of other medications remains unknown. Focusing on pharmacotherapy in diabetes may prevent bone mineral disorders and influence both the treatment and quality of life in patients suffering from diabetes mellitus. On the other hand, anti-osteoporosis drugs, such as antiresorptive or anabolic drugs, as well as drugs with a mixed mechanism of action, may affect carbohydrate metabolism, particularly in patients with diabetes. Therefore, the treatment of diabetes as well as osteoporosis prevention are vital for this group of patients.

The synergistic effect of diabetes mellitus and osteoporosis on the all-cause mortality: a cohort study of an American population

“…However, further investigation is necessary to gain a more comprehensive understanding of the precise impact of bone marrow fat on bone formation. In addition, a study noted that the effect of osteoporosis on carbohydrate metabolism is significant, especially in individuals diagnosed with DM ( 21 ). Because of the interaction between DM and osteoporosis, we suspect that the higher death risk of patients with both diseases is not the result of the superposition of the death risks of the two diseases.…”

“…Conversely, it is not advisable for diabetic patients with bone mineral disorders to take sulfonylureas (due to the potential for hypoglycemia) or thiazolidinediones (due to their mechanism of action). The impact of newer antidiabetic medications like sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP4) inhibitors on bone health and DM remains uncertain, as there is insufficient data available ( 21 ).…”

Gastrodin improves osteoblast function and adhesion to titanium surface in a high glucose environment

“…Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, accounting for 90–95% of all cases and is expected to increase to 439 million cases globally by 2030 [ 2 , 3 ]. Diabetic patients are often susceptible to osteoporosis [ 4 ]. In addition, they have a higher incidence of periodontitis and tooth loss than healthy people [ 5 ].…”

Text Mining and Drug Discovery Analysis: A Comprehensive Approach to Investigate Diabetes-Induced Osteoporosis

“…In addition, the interplay of choices takes center stage, with the selection of medication for patients ensnared in the clutches of both OP and diabetes evolving into a matter of paramount importance. The alluring first-line drug recommendation of bisphosphonates for OP therapy in diabetes-stricken patients whispers the promise of a brighter future [6]. Scientific research verified that metformin has a positive effect on bone mineral density (BMD) in diabetics [7,8].…”